DK3166973T3 - Immunstimulerende monoklonale antistoffer mod human interleukin-2 - Google Patents
Immunstimulerende monoklonale antistoffer mod human interleukin-2 Download PDFInfo
- Publication number
- DK3166973T3 DK3166973T3 DK15759938.2T DK15759938T DK3166973T3 DK 3166973 T3 DK3166973 T3 DK 3166973T3 DK 15759938 T DK15759938 T DK 15759938T DK 3166973 T3 DK3166973 T3 DK 3166973T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunstimulating
- monoclonal antibodies
- antibodies against
- against human
- human interleukin
- Prior art date
Links
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title 1
- 102000055277 human IL2 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176619 | 2014-07-10 | ||
| PCT/IB2015/055226 WO2016005950A1 (en) | 2014-07-10 | 2015-07-10 | Immune-stimulating monoclonal antibodies against human interleukin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3166973T3 true DK3166973T3 (da) | 2020-04-06 |
Family
ID=51162588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15759938.2T DK3166973T3 (da) | 2014-07-10 | 2015-07-10 | Immunstimulerende monoklonale antistoffer mod human interleukin-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894828B2 (enExample) |
| EP (2) | EP3166973B1 (enExample) |
| JP (1) | JP7209464B2 (enExample) |
| CN (1) | CN106604932B (enExample) |
| AU (1) | AU2015287227B2 (enExample) |
| CA (1) | CA2954476C (enExample) |
| DK (1) | DK3166973T3 (enExample) |
| ES (2) | ES2989669T3 (enExample) |
| WO (1) | WO2016005950A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260218B2 (en) | 2016-01-11 | 2023-04-01 | Novartis Ag | Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins |
| KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
| GB201621806D0 (en) * | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| EP3585404A4 (en) * | 2017-02-23 | 2021-04-14 | City of Hope | METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD) |
| CA3057146A1 (en) | 2017-03-23 | 2018-09-27 | The Trustees Of The University Of Pennsylvania | Anti-c5a antibodies and uses thereof |
| AU2018271751B2 (en) * | 2017-05-25 | 2021-04-01 | Institute For Basic Science | Anti-human interleukin-2 antibodies and uses thereof |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2023509991A (ja) | 2020-01-13 | 2023-03-10 | シンアフィックス ビー．ブイ． | 抗体及び免疫細胞エンゲージャーのコンジュゲート |
| CN115397852B (zh) | 2020-02-16 | 2023-08-11 | 奥罗斯生物科学公司 | 工程化抗il-2抗体 |
| CA3189257A1 (en) * | 2020-08-18 | 2022-02-24 | Universitat Zurich | A cd25-biased anti-il-2 antibody |
| CN117157107A (zh) | 2021-02-08 | 2023-12-01 | 西纳福克斯股份有限公司 | 多功能抗体 |
| CA3234995A1 (en) | 2021-10-14 | 2023-04-20 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
| CN119912559B (zh) * | 2025-01-22 | 2025-12-26 | 贵州中医药大学 | 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用 |
| CN119775409B (zh) * | 2025-03-05 | 2025-07-11 | 深圳真实生物医药科技有限公司 | 靶向sost的抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK174501B1 (da) | 1983-12-23 | 2003-04-28 | Hoffmann La Roche | Fremgangsmåde til fremstilling af interleukin-2 |
| DK134487A (da) * | 1986-03-17 | 1987-09-18 | Hoffmann La Roche | Monoklonalt antistof med affinitet for humant interleukin-2 |
| DK0920505T3 (da) | 1996-08-16 | 2008-09-08 | Schering Corp | Pattedyrcelleoverfladeantigener og tilhörende reagenser |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| EP1578419A4 (en) | 2002-12-30 | 2008-11-12 | 3M Innovative Properties Co | IMMUNOSTIMULATING COMBINATIONS |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| EP1888644A1 (en) | 2005-06-01 | 2008-02-20 | Micromet AG | Anti-il2 antibodies |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| US20100310501A1 (en) * | 2006-02-16 | 2010-12-09 | Onur Boyman | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject |
| CN101045923B (zh) * | 2006-03-31 | 2011-11-23 | 沈阳三生制药有限责任公司 | 生产一种白细胞介素类似物的方法 |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| ME03661B (me) | 2010-08-12 | 2020-07-20 | Lilly Co Eli | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba |
| TWI666027B (zh) | 2011-02-10 | 2019-07-21 | 羅齊克雷雅公司 | 突變介白素-２多肽 |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
-
2015
- 2015-07-10 DK DK15759938.2T patent/DK3166973T3/da active
- 2015-07-10 ES ES20158066T patent/ES2989669T3/es active Active
- 2015-07-10 AU AU2015287227A patent/AU2015287227B2/en not_active Ceased
- 2015-07-10 CN CN201580048027.0A patent/CN106604932B/zh active Active
- 2015-07-10 JP JP2017501280A patent/JP7209464B2/ja active Active
- 2015-07-10 EP EP15759938.2A patent/EP3166973B1/en active Active
- 2015-07-10 EP EP20158066.9A patent/EP3693389B1/en active Active
- 2015-07-10 WO PCT/IB2015/055226 patent/WO2016005950A1/en not_active Ceased
- 2015-07-10 US US15/324,468 patent/US10894828B2/en active Active
- 2015-07-10 ES ES15759938T patent/ES2779977T3/es active Active
- 2015-07-10 CA CA2954476A patent/CA2954476C/en active Active
-
2020
- 2020-12-22 US US17/131,221 patent/US20210230269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2779977T3 (es) | 2020-08-21 |
| ES2989669T3 (es) | 2024-11-27 |
| JP7209464B2 (ja) | 2023-01-20 |
| AU2015287227A1 (en) | 2017-02-09 |
| EP3693389C0 (en) | 2024-09-04 |
| CN106604932A (zh) | 2017-04-26 |
| WO2016005950A1 (en) | 2016-01-14 |
| US20210230269A1 (en) | 2021-07-29 |
| US10894828B2 (en) | 2021-01-19 |
| EP3166973B1 (en) | 2020-02-19 |
| EP3693389B1 (en) | 2024-09-04 |
| CN106604932B (zh) | 2024-12-10 |
| AU2015287227A8 (en) | 2017-02-16 |
| EP3166973A1 (en) | 2017-05-17 |
| JP2017525343A (ja) | 2017-09-07 |
| CA2954476A1 (en) | 2016-01-14 |
| EP3693389A1 (en) | 2020-08-12 |
| CA2954476C (en) | 2023-09-19 |
| EP3693389A9 (en) | 2021-04-07 |
| AU2015287227B2 (en) | 2021-02-18 |
| US20170183403A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| HUE060019T2 (hu) | Anti-LAG3 antitestek | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3166973T3 (da) | Immunstimulerende monoklonale antistoffer mod human interleukin-2 | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| SI3354729T1 (sl) | Protitelesa anti-garp | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| EP3684806A4 (en) | NEW ANTI-CD3EPSILON ANTIBODIES | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| EP3835319C0 (en) | Humanized Anti-ACTH Antibodies and Their Use | |
| PL3215530T3 (pl) | Ulepszone przeciwciała anty-il-6 | |
| DK3154583T3 (da) | Humane monoklonale antistoffer mod gangliosid gd2 | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3452515T3 (da) | Her-2-bindende antistoffer |